Plain-English translation of NCT05853952 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a pilot study testing a non-invasive neuromodulation device called NESA X-Signal to see if it can help people recover better after a stroke. About 30 people who have had a stroke will receive 20 sessions of treatment with this device. The researchers want to understand whether this treatment is feasible and helpful before running a larger study.
Many people are left with lasting problems after a stroke, like weakness or difficulty moving. This trial is exploring whether this non-invasive brain stimulation device could be a helpful addition to regular rehabilitation therapy to improve recovery.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to either receive real brain stimulation or a placebo (sham) treatment—neither you nor your physiotherapist will know which you're getting. You will attend 20 one-hour treatment sessions with the NESA X-Signal device. The study uses this blinded approach so researchers can fairly measure whether the real treatment works better than placebo.
AI-generated summary from trial data · Jul 22, 2026 · Not medical advice
Spain
Sponsor
University of Las Palmas de Gran Canaria
Enrollment target
~30 participants
Started
April 2023
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mariola Lledó Amat, MSc
University of Las Palmas de Gran Canaria
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.